Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

(2012) Lomon So et al.   BIOCHEMICAL JOURNAL

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

(2011) Stephen Jamieson et al.   BIOCHEMICAL JOURNAL

Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN- +IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors

(2011) N. A. Marshall et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)

(2011) Gordon W. Rewcastle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms

(2011) Pixu Liu et al.   NATURE MEDICINE

PI3K  Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

(2011) D. A. Fruman et al.   Cancer Discovery

PI3K p110  regulates T-cell cytokine production during primary and secondary immune responses in mice and humans

(2010) D. R. Soond et al.   BLOOD

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

(2010) Kavya Rakhra et al.   CANCER CELL

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

(2010) K. A. Edgar et al.   CANCER RESEARCH

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

(2010) P. Workman et al.   CANCER RESEARCH

Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

(2010) C. O'Brien et al.   CLINICAL CANCER RESEARCH

Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction

(2010) J. Rolf et al.   JOURNAL OF IMMUNOLOGY

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cancer-derived mutations in the regulatory subunit p85  of phosphoinositide 3-kinase function through the catalytic subunit p110 

(2010) M. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The PI3K Isoforms p110  and p110  Are Essential for Pre-B Cell Receptor Signaling and B Cell Development

(2010) F. Ramadani et al.   Science Signaling

Targeting the PI3K signaling pathway in cancer

(2009) Kwok-Kin Wong et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Phosphoinositide 3-Kinase p110  Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses

(2009) C. A. Durand et al.   JOURNAL OF IMMUNOLOGY

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

(2009) F. I. Raynaud et al.   MOLECULAR CANCER THERAPEUTICS

Genetic or pharmaceutical blockade of p110δ phosphoinositide 3-kinase enhances IgE production

(2008) Ting-ting Zhang et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

(2008) Mariona Graupera et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA